Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Dec 7;95(2):297–308. doi: 10.3945/ajcn.111.024927

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 American Society for Nutrition

This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/license/) which permit unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FIGURE 4. — Effects of PHEN/TPM CR on cardiometabolic variables. LS mean changes (95% CI) in (A) blood pressure, (B) antihypertensive medications, (C) lipid variables, (D) lipid-lowering medications, (E) Hb A_1c, and (F) antidiabetic medications from baseline (week 0) to week 108 (ITT-LOCF). Changes in Hb A_1c represent the T2D subgroup. Changes in concomitant medications represent the safety study. Standardized lifestyle intervention was used across all treatment groups. *Percentage increase minus percentage decrease; P < 0.05 for between-group differences. ^†P < 0.01 compared with placebo; ^‡P < 0.0001 compared with placebo. Hb A_1c, glycated hemoglobin; HDL-C, HDL cholesterol; ITT, intent-to-treat; LDL-C, LDL cholesterol; LOCF, last observation carried forward; LS, least-squares; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate; T2D, type 2 diabetes.